Physician profile
Cassie Hackman
NPI 1750886966
$385.76
in general payments reported to CMS, 2019-2025
12 companies · $17.27 in 2025
The $17.27 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $187 · 2022: $123 · 2023: $38.78 · 2024: $19.53 · 2025: $17.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $75.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $75.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $85.42 | 2021-2022 | |
| Abbvie INC. | $69.31 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.39 | 2021-2022 | |
| Amarin Pharma, INC. | $29.55 | 2021 | |
| Lilly USA, LLC | $27.68 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.94 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.91 | 2023 | Quviviq |
| Abbott Laboratories | $17.60 | 2021 | |
| Revance Therapeutics, INC. | $17.27 | 2025 | Daxxify |
| Sanofi-Aventis U.S. LLC | $14.52 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.48 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassie Hackman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.